Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA panel snubs Johnson & Johnson’s rheumatoid arthritis drug sirukumab, citing worries about trial

fiercebiotechAugust 07, 2017

Tag: drug sirukumab , trial deaths

PharmaSources Customer Service